Company news
Beijing Tiantan Biological Products Corporation Limited Class A (SSE:600161) news
Beijing Tiantan Biological Products Corporation Limited Class A news releases on 6ix. Latest, Jan 21, 2025: Announcement on 2024 Annual Preliminary Earnings…
View Beijing Tiantan Biological Products Corporation Limited Class A →
Press releases — page 2
Announcement on 2024 Annual Preliminary Earnings Estimate
January 20, 2025
Announcement on Subsidiary Obtaining Summary Report on Clinical Trial
December 31, 2024
Announcement on Asset Leasing and Related Party Transactions
December 30, 2024
Announcement on Termination of Drug Clinical Trial of Subsidiary
December 27, 2024
Announcement on Resignation of Senior Officer
December 20, 2024
Announcement on Resolutions of 17th Meeting of 9th Board of Directors
December 18, 2024
Announcement on Resignation of Deputy General Manager and Secretary of the Board of Directors
November 28, 2024
Announcement on Resignation of Director
November 25, 2024
Announcement on Obtaining Clinical Trial Summary Report by Affiliated Enterprise
November 22, 2024
Announcement on Convening the Q3 2024 Performance Briefing
October 31, 2024
Report for Q3 2024
October 25, 2024
Announcement on the Progress of Chengdu Rongsheng Pharmaceuticals Co., Ltd. Acquiring 100% Equity of Wuhan Zhongyuan Ruide Biological Products Co., Ltd.
October 21, 2024